Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Demonstrate significant bleed reduction in hemophilia A and B
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Subscribe To Our Newsletter & Stay Updated
